Delivering Fertility Options into Daily Life: Fertility Timing Method Kit "meeta Syringe" to be Featured in In-Train Advertisements on 4 Tokyo Metropolitan Subway Lines

Concerns and anxieties about fertility treatments can be difficult to discuss with others, and it may take time to find the necessary information.

Pass Create Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo, Representative Director: Takaaki Iihara) will be displaying in-train window advertisements for the fertility timing method kit "meeta Syringe" on four Tokyo Metropolitan Subway lines (Oedo Line, Mita Line, Shinjuku Line, Asakusa Line) operated by the Tokyo Metropolitan Government Bureau of Transportation, from July 1 to July 31, 2026, as an opportunity to learn about fertility options in daily life.

Through these advertisements on the four Tokyo Metropolitan Subway lines, which are used by approximately 2.64 million people daily, we aim to deliver options to those who need information about fertility treatments and to broaden opportunities for society as a whole to naturally encounter discussions about fertility.

Background

Declining birthrates have been a long-standing social issue discussed in Japan.

According to the Vital Statistics of Japan from the Ministry of Health, Labour and Welfare, there is a continuing downward trend in the number of births and the total fertility rate nationwide.

On the other hand, fertility concerns and anxieties are often difficult to discuss with others, making it a topic where individuals tend to bear the burden of information gathering and considering options.

We believe that establishing an environment where information on diverse options is accessible from the pre-conception stage will become increasingly important in the future.

Pass Create Co., Ltd. is working to expand opportunities to easily access information related to fertility treatments by increasing awareness of the fertility timing method kit "meeta Syringe."

Previously, in-train advertisements were conducted on the "Nagoya Municipal Subway Higashiyama Line in December 2025," "Fukuoka City Subway Airport Line, Hakozaki Line, and Nanakuma Line in January 2026," and "Sendai City Subway Namboku Line in April 2026."

In these initiatives, searches for the keyword "meeta" temporarily increased in the surrounding areas during and after the advertising period, showing a trend towards positive reception, and our internal data confirmed a certain level of impact as an awareness-raising measure.

Based on this feedback, we will be deploying advertisements on the four Tokyo Metropolitan Subway lines: Oedo, Mita, Shinjuku, and Asakusa.

We aim to make fertility options more familiar to the many residents of the Tokyo metropolitan area who use these transportation spaces in their daily lives.

Tokyo's Births and Total Fertility Rate

In Tokyo, where advertisements will be placed, the number of births in 2025 increased for the first time in 10 years. However, the total fertility rate remained at 0.96, the same level as the previous year, indicating a continued low level.

While government support for childcare is being enhanced, creating an environment where information on diverse options is accessible from the pre-conception stage is also becoming important.

Source: Based on the Ministry of Health, Labour and Welfare's "Outline of the 2025 Vital Statistics Monthly Report - Annual Summary (Preliminary Figures)" and Tokyo Metropolitan Government's "2024 Tokyo Vital Statistics Annual Report (Final Figures)," prepared by our company.

In this context, we believe that informing people about the various options available for fertility treatments can serve as a catalyst for considering fertility methods that suit them.

For couples and partners balancing work and daily life with fertility treatments, the syringe method is one way to incorporate fertility support at home, even if they find it burdensome to adjust the timing of intercourse.

What is the Fertility Timing Method Kit "meeta Syringe"?

Home Fertility Timing Method Kit "meeta Syringe 10 Uses"

"meeta Syringe" is a home fertility kit registered as a general medical device.

It is offered as a product to support fertility treatments, which have been gaining interest in recent years, and is designed to be used at home in conjunction with timing methods, under the supervision of a physician.

It features a shape designed with consideration for the physique of Japanese women, and its "simple 3-step" usage procedure means it requires no special knowledge or equipment.

*Usage experience and perception may vary by individual.

[Baby Life Lab Official Website]

https://babylife-lab.com/

Future Outlook

Through transportation advertising, Pass Create Co., Ltd. is working to create a society where everyone can naturally access information and learn about fertility methods that suit them, rather than isolating fertility treatments as something special.

The current advertisement placement on the four Tokyo Metropolitan Subway lines further advances this initiative.

Pass Create Co., Ltd. will continue to provide appropriate information on various fertility options, including the "meeta Syringe" method, and contribute to the environment surrounding fertility treatments by promoting fertility as something more accessible and positive within society.

Company Overview (Pass Create Co., Ltd.)

Head Office Location: 1-8-4 Shinjuku, Shinjuku-ku, Tokyo, Kintetsu Shinjuku Gyoen Building 9F

Established: November 25, 2008

Capital: 10,000,000 yen

Representative: Takaaki Iihara, Representative Director

Business Activities: Planning, development, and sales of healthcare products / Owned media business / SES business / Staffing business / Online school business

Medical Device Approval: Class III Marketing Approval for Medical Devices 13B3X10286 / Manufacturing Business for Medical Devices 13BZ201388

[Contact Information for Inquiries]

Healthcare Business Customer Center

Free Dial: 0120-905-147

e-mail: info@babylife-lab.com